We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.05 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
From May 2019 to May 2024
TIDMRENE
RNS Number : 8054V
ReNeuron Group plc
10 April 2019
10 April 2019 AIM: RENE
ReNeuron Group plc
Director/PDMR Interest in Shares and Share Options
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that the following share option grants were made today under the Company's Long Term Incentive Plan (the "Plan"), its US Incentive Stock Option Plan (the "US Plan") and its Non-Executive Share Option Scheme to directors and Persons Discharging Managerial Responsibilities (PDMRs) listed below.
The Plan allows the Company to grant tax-advantaged share options under a Company Share Option Plan (the "CSOP Plan"), as well as non-tax advantaged options. Where capacity exists for a director/PDMR to be issued share options under the CSOP Plan, these options are issued in parallel with non tax-advantaged options. The figures per individual below, where applicable and except where indicated, therefore comprise parallel grants of both CSOP Plan share options and non tax-advantaged share options, the terms of each grant ensuring that the exercise of one type of option reduces the number exercisable under the other type of option on a share for share basis. Individuals can therefore elect, subject to their tax status, which specific option grant (CSOP or non tax-advantaged options) they exercise.
The Plan also allows the Company to grant Incentive Stock Options ("ISOs") under the US Plan, as well as a conditional right to receive shares ("Conditional Rights") to employees in the US. Where a US employee is issued ISOs under the US Plan, these options are issued in parallel with Conditional Rights. The figures per individual below, where applicable and except where indicated, therefore comprise parallel grants of both ISOs and Conditional Rights, the terms of each grant ensuring that the exercise of one type of option or right reduces the number that vest under the other type of option or right on a share for share basis. The Conditional Rights are granted at nominal value and the ISOs have an exercise price of 222 pence per share being the closing price of the Company's shares on 09 April 2019.
Share options granted under the CSOP Plan are over shares up to an aggregate market value of GBP30,000 (measured at the date of grant) and with an exercise price of 222 pence per share, being the closing mid-market price of the Company's shares on 09 April 2019. Non tax-advantaged options are granted at nominal value.
Share options granted under the Plan and the US Plan (unless otherwise stated) are exercisable from the third anniversary of the award and are subject to the achievement of the following performance conditions:
1) When the Company has signed out-licensing deal(s) for any of its technologies or programmes which, together with other financial resources, provides sufficient funding to allow the achievement of clinical proof of concept data for the CTX and hRPC programmes, one third of the options will vest.
2) When the Company's share price has doubled from the price at the date of grant, one third of the options will vest.
3) When the sixth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest.
The Non-Executive Directors of the Company are remunerated partly in cash and partly in the form of share options granted under the Non-Executive Share Option Scheme. In order to remove as far as possible any incentive element that might influence the Non-Executive Directors' independence, share options are granted at nominal value without performance conditions attaching and vest over three years on a straight line basis.
Share option grants are deemed accepted by the option holder unless expressly rejected within a period of 30 days from the date of grant.
Hot Features
Premium
Name Title Date of Total shares Percentage
grant Number over which of issued
of share of share options shares
options options are held under option
(i) granted (post award)
Chief Medical 10 April
Richard Beckman(ii) Officer 2019 146,946 300,528 0.95%
---------------------- ----------- ---------- -------------- --------------
Non-executive 10 April
John Berriman Chairman 2019 6,000 54,252 0.17%
---------------------- ----------- ---------- -------------- --------------
Non-executive 10 April
Simon Cartmell Director 2019 6,000 54,252 0.17%
---------------------- ----------- ---------- -------------- --------------
Non-executive 10 April
Tim Corn Director 2019 6,000 47,452 0.15%
---------------------- ----------- ---------- -------------- --------------
10 April
Randolph Corteling Head of Research 2019 36,800 190,301 0.60%
---------------------- ----------- ---------- -------------- --------------
Non-executive 10 April
Claudia D'Augusta Director 2019 6,000 28,700 0.09%
---------------------- ----------- ---------- -------------- --------------
Non-executive 10 April
Chris Evans Director 2019 6,000 41,700 0.13%
---------------------- ----------- ---------- -------------- --------------
VP Development
& General Manager 10 April
Sharon Grimster - Wales 2019 70,000 318,821 1.01%
---------------------- ----------- ---------- -------------- --------------
John Hawkins 10 April
(iii) Financial Controller 2019 20,000 40,000 0.13%
---------------------- ----------- ---------- -------------- --------------
Chief Executive 10 April
Olav Hellebo Officer 2019 260,861 1,066,721 3.37%
---------------------- ----------- ---------- -------------- --------------
Chief Financial 10 April
Michael Hunt Officer 2019 103,785 556,002 1.76%
---------------------- ----------- ---------- -------------- --------------
Non-executive 10 April
Mike Owen Director 2019 6,000 31,700 0.10%
---------------------- ----------- ---------- -------------- --------------
Head of Regulatory 10 April
Shaun Stapleton Affairs 2019 58,000 275,897 0.87%
---------------------- ----------- ---------- -------------- --------------
10 April
Paula Thornton(iii) HR Director 2019 12,000 20,000 0.06%
---------------------- ----------- ---------- -------------- --------------
(i) The option grants are under the non-tax advantaged scheme and (where capacity exists) the CSOP Plan (as detailed above) save for (ii) below, which has been granted under the US Plan, and the Non-Executive Directors' grants.
(ii) The grant to Dr Beckman includes the grant of ISOs under the US Plan and Conditional Rights under The Plan. These options or rights are exercisable subject to achievement of performance conditions (1) to (3) above. The ISOs and Conditional Rights vest from the second anniversary of grant onwards, the ISOs being subject to an annual $100,000 limit based on the aggregate fair value of shares subject to grant measured on the date of grant.
(iii) The grants to Mr Hawkins and Mrs Thornton are made under The Plan and are exercisable subject to achievement of performance conditions (1) and (3) above, with 50% of the options becoming exercisable in each case.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.
SENQUIRIES:
ReNeuron +44 (0)20 3819 8400 Olav Hellebø , Chief Executive Officer Michael Hunt, Chief Financial Officer Buchanan +44 (0) 20 7466 5000 Mark Court, Sophie Cowles, Tilly Abraham Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600 Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) Nplus1 Singer Advisory LLP +44 (0) 20 7496 3000 Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
(Disclosure in relation to share options granted to Directors and PDMRs)
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name John Berriman
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Chairman
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 6,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Richard Beckman
--------------------------- ----------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Chief Medical Officer
--------------------------- ----------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------- ----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name ReNeuron Group plc
--------------------------- ----------------------------------------------
b) LEI 2138003TU12CQ5TZO137
--------------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
---------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
--------------------------- ----------------------------------------------
b) Nature of the transaction Grant of share options and conditional rights
--------------------------- ----------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 146,946
----------
--------------------------- ----------------------------------------------
d) Aggregated information N/A
--------------------------- ----------------------------------------------
e) Date of the transaction Granted 10 April 2019
--------------------------- ----------------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- ----------------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Simon Cartmell
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 6,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Tim Corn
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 6,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Randolph Corteling
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Head of Research
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 36,800
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Claudia D'Augusta
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 6,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Chris Evans
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 6,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Sharon Grimster
----------------------------- ------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status VP Development & General Manager - Wales
----------------------------- ------------------------------------------
b) Initial notification Initial notification
/Amendment
----------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
----------------------------- ------------------------------------------
b) LEI 2138003TU12CQ5TZO137
----------------------------- ------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
----------------------------- ------------------------------------------
b) Nature of the transaction Grant of share options
----------------------------- ------------------------------------------
Price(s) and volume(s) Price(s) Volume(s)
1p 70,000
----------
----------------------------- ------------------------------------------
d) Aggregated information N/A
----------------------------- ------------------------------------------
e) Date of the transaction Granted 10 April 2019
----------------------------- ------------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------- ------------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name John Hawkins
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Financial Controller
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 20,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Olav Hellebo
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 260,861
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Michael Hunt
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Financial Officer
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 103,785
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Mike Owen
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 6,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Shaun Stapleton
------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Head of Regulatory Affairs
------------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
------------------------------------ -----------------------------------
b) LEI 2138003TU12CQ5TZO137
------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
------------------------------------ -----------------------------------
b) Nature of the transaction Grant of share options
------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 58,000
----------
------------------------------------ -----------------------------------
d) Aggregated information N/A
------------------------------------ -----------------------------------
e) Date of the transaction Granted 10 April 2019
------------------------------------ -----------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------ -----------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Paula Thornton
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status HR Director
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 12,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 10 April 2019
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHFMGMDFGFGLZM
(END) Dow Jones Newswires
April 10, 2019 09:37 ET (13:37 GMT)
1 Year Reneuron Chart |
1 Month Reneuron Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
